Register Login

All Posts

Caplacizumab Immune-mediated TTP Clinical Efficacy Report

Thanks to colleague X. Long Zheng, MD, for his LinkedIn heads-up announcing the 31 March 2025 eClinicalMedicine release of Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project). This pivotal open-access article compares patient mortality rate and the response rate to caplacizumab (Cablivi®) to standard care.
read more